Literature DB >> 22318756

Bisphosphonates: effects on osteoblast.

Nicola Maruotti1, Addolorata Corrado, Anna Neve, Francesco Paolo Cantatore.   

Abstract

PURPOSE: Bisphosphonates are synthetic analogues of pyrophosphate usually used in treating bone disorders such as osteoporosis, Paget's disease, fibrous dysplasia, hypercalcemia of malignancy, and inflammation-related bone loss. Though therapeutic effects of bisphosphonates depend primarily on their inhibitory effect on osteoclasts, increasing attention is being given to other effector cells, such as osteoblasts. This review focuses on the presumed effect of bisphosphonates on osteoblasts.
METHODS: A review of the literature was conducted to evaluate the pharmacodynamic effects of bisphosphonates including inhibition of osteoclasts and apoptosis of osteocytes and osteoblasts as well as their potential stimulatory effects on the proliferation of osteoblasts.
RESULTS: Studies have demonstrated that bisphosphonates may stimulate proliferation of osteoblasts and inhibit apoptosis of osteocytes and osteoblasts.
CONCLUSION: Considering that osteoblasts may be involved in bone disorders, such as osteoporosis, osteopetrosis, osteogenesis imperfecta, and Paget's disease, and that bisphosphonates may stimulate proliferation of osteoblasts and inhibit apoptosis of osteocytes and osteoblasts, it is conceivable that a role for bisphosphonates exists in these diseases beyond merely the osteoclast influence.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22318756     DOI: 10.1007/s00228-012-1216-7

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  74 in total

Review 1.  Therapeutic approaches to bone diseases.

Authors:  G A Rodan; T J Martin
Journal:  Science       Date:  2000-09-01       Impact factor: 47.728

Review 2.  Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability.

Authors:  Teresita Bellido; Lilian I Plotkin
Journal:  Bone       Date:  2010-08-18       Impact factor: 4.398

Review 3.  Bisphosphonates: mechanisms of action.

Authors:  G A Rodan; H A Fleisch
Journal:  J Clin Invest       Date:  1996-06-15       Impact factor: 14.808

4.  IL-1 mediates TNF-induced osteoclastogenesis.

Authors:  Shi Wei; Hideki Kitaura; Ping Zhou; F Patrick Ross; Steven L Teitelbaum
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

5.  Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect.

Authors:  Francis H Glorieux; Leanne M Ward; Frank Rauch; Ljiljana Lalic; Peter J Roughley; Rose Travers
Journal:  J Bone Miner Res       Date:  2002-01       Impact factor: 6.741

Review 6.  Paget's disease.

Authors:  I B Bender
Journal:  J Endod       Date:  2003-11       Impact factor: 4.171

7.  High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties.

Authors:  Samantha Pozzi; Sonia Vallet; Siddhartha Mukherjee; Diana Cirstea; Nileshwari Vaghela; Loredana Santo; Eyal Rosen; Hiroshi Ikeda; Yutaka Okawa; Tanyel Kiziltepe; Jesse Schoonmaker; Wanling Xie; Teru Hideshima; Edie Weller; Mary L Bouxsein; Nikhil C Munshi; Kenneth C Anderson; Noopur Raje
Journal:  Clin Cancer Res       Date:  2009-09-08       Impact factor: 12.531

8.  Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease.

Authors:  L M Ward; F Rauch; R Travers; G Chabot; E M Azouz; L Lalic; P J Roughley; F H Glorieux
Journal:  Bone       Date:  2002-07       Impact factor: 4.398

9.  Osteoblast proliferation and maturation by bisphosphonates.

Authors:  Gun-Il Im; Sheeraz A Qureshi; Jennifer Kenney; Harry E Rubash; Arun S Shanbhag
Journal:  Biomaterials       Date:  2004-08       Impact factor: 12.479

10.  Inhibition of osteoblast function in vitro by aminobisphosphonates.

Authors:  Isabel R Orriss; Michelle L Key; Kay W Colston; Timothy R Arnett
Journal:  J Cell Biochem       Date:  2009-01-01       Impact factor: 4.429

View more
  24 in total

1.  Low concentrations of zoledronic acid are better at regulating bone formation and repair.

Authors:  Xiaomeng Yang; Yanqin Lu; Zhiliang Li; Yanzhou Wang; Fei Zhao; Jinxiang Han
Journal:  Intractable Rare Dis Res       Date:  2013-02

2.  Effects of pyrophosphate delivery in a peritoneal dialysis solution on bone tissue of apolipoprotein-E knockout mice with chronic kidney disease.

Authors:  Fellype C Barreto; Rodrigo B de Oliveira; Joyce Benchitrit; Loïc Louvet; Raja Rezg; Sabrina Poirot; Vanda Jorgetti; Tilman B Drüeke; Bruce L Riser; Ziad A Massy
Journal:  J Bone Miner Metab       Date:  2014-01-21       Impact factor: 2.626

3.  Restoration of osteogenic differentiation by overexpression of cannabinoid receptor 2 in bone marrow mesenchymal stem cells isolated from osteoporotic patients.

Authors:  Bangjun Wang; Kai Lian; Jun Li; Gang Mei
Journal:  Exp Ther Med       Date:  2017-10-24       Impact factor: 2.447

4.  Periosteal microcirculatory reactions in a zoledronate-induced osteonecrosis model of the jaw in rats.

Authors:  Ágnes Janovszky; Andrea Szabó; Renáta Varga; Dénes Garab; Mihály Boros; Csilla Mester; Nikolett Beretka; Tamás Zombori; Hans-Peter Wiesmann; Ricardo Bernhardt; Imre Ocsovszki; Péter Balázs; József Piffkó
Journal:  Clin Oral Investig       Date:  2014-10-30       Impact factor: 3.573

5.  The effect of laser therapy on the expression of osteocalcin and osteopontin after tooth extraction in rats treated with zoledronate and dexamethasone.

Authors:  Giovanni Mergoni; Paolo Vescovi; Roberto Sala; Elisabetta Merigo; Pietro Passerini; Roberta Maestri; Domenico Corradi; Paolo Govoni; Samir Nammour; Massimiliano G Bianchi
Journal:  Support Care Cancer       Date:  2015-07-21       Impact factor: 3.603

6.  Serum creatine kinase isoenzymes in children with osteogenesis imperfecta.

Authors:  P D'Eufemia; R Finocchiaro; A Zambrano; V Lodato; L Celli; S Finocchiaro; P Persiani; A Turchetti; M Celli
Journal:  Osteoporos Int       Date:  2016-08-25       Impact factor: 4.507

Review 7.  Lipids in the Bone Marrow: An Evolving Perspective.

Authors:  Elizabeth Rendina-Ruedy; Clifford J Rosen
Journal:  Cell Metab       Date:  2019-10-24       Impact factor: 27.287

8.  Zoledronic acid modulates osteoclast apoptosis through activation of the NF-κB signaling pathway in ovariectomized rats.

Authors:  Yu-Ting Cheng; Jian Liao; Qian Zhou; Hua Huo; Lucas Zellmer; Zheng-Long Tang; Hong Ma; Wei Hong; Dezhong Joshua Liao
Journal:  Exp Biol Med (Maywood)       Date:  2021-04-29

Review 9.  Basic research and clinical applications of bisphosphonates in bone disease: what have we learned over the last 40 years?

Authors:  Xiao-Long Xu; Wen-Long Gou; Ai-Yuan Wang; Yu Wang; Quan-Yi Guo; Qiang Lu; Shi-Bi Lu; Jiang Peng
Journal:  J Transl Med       Date:  2013-12-11       Impact factor: 5.531

10.  Puerarin Suppress Apoptosis of Human Osteoblasts via ERK Signaling Pathway.

Authors:  Ling-Juan Liu; Li-Qun Liu; Tao Bo; Shi-Jun Li; Zhen Zhu; Rong-Rong Cui; Ding-An Mao
Journal:  Int J Endocrinol       Date:  2013-06-12       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.